Pluvicto™ shows statistically significant & clinically meaningful rPFS benefit in patients with PSMA+ve metastatic CRPC December 12, 2022
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 November 23, 2022
Lynparza – abiraterone combo recommended for approval in the EU by CHMP in 1L metastatic CRPC November 23, 2022
First Patient Successfully Dosed in Ph 1 Study of Pindnarulex in Combination with Talazoparib for the Treatment of Prostate Cancer November 16, 2022
Enrollment into Ph 1 study of EPI-7386 with apalutamide/abiraterone acetate plus prednisone in metastatic CRPC patients suspended due to operational recruitment challenges November 16, 2022
TRITON3 Ph 3 Trial Of Rubraca Achieves Primary Endpoint In Men With metastatic CRPC With BRCA Or ATM Mutations October 12, 2022
Ph 3 TALAPRO-2 study of TALZENNA® + XTANDI® in metastatic CRPC patients met primary endpoint of rPFS vs placebo plus XTANDI October 12, 2022
